Stop, Stay or Switch? A Cleveland Clinic Study of 20,486 GLP-1 Patients Tracked Weight for Two Years

Many people stop or switch their GLP-1 medicine. A large Cleveland Clinic records study presented at ObesityWeek compared what happened to weight two years later. Here is what it found and what it cannot tell you.

Order Meals — View This Week's Menu

By Lew Kizer — 2026-11-19 — Health & Nutrition

The short answer

In a Cleveland Clinic study of 20,486 adults who started weekly semaglutide or tirzepatide, people who stopped treatment were down 3.9% of body weight on average at two years. People who kept taking their original medicine were down 10.9%, and people who switched between semaglutide and tirzepatide were down 16%. It was an observational records study, so it shows associations, not cause and effect.

Key facts

  • Presented at ObesityWeek 2026 (Nov. 14-17) by Hamlet Gasoyan, PhD, of the Cleveland Clinic; reported by Healio on Nov. 14, 2026.
  • Design: a target trial emulation using Cleveland Clinic electronic health records from 2021 to 2025.
  • 20,486 adults with type 2 diabetes or obesity on injectable, once-weekly semaglutide or tirzepatide. Average age 56.7; 63% women; 73.4% started on semaglutide.
  • Two-year average weight change by path: stopped treatment -3.9%; switched to another obesity drug -8.1%; continued original medicine -10.9%; switched between semaglutide and tirzepatide -16%; bariatric surgery -26.6%.
  • People who started on semaglutide and switched to tirzepatide lost about 3 kg more than those who stayed on semaglutide.
  • People who started on tirzepatide and stayed on it lost about 4.5 kg more than those who switched to semaglutide.
  • A1C and systolic blood pressure moved in a similar pattern to body weight.

KINGSPORT, Tenn., Nov. 19, 2026 — A lot of people who start a GLP-1 medicine do not stay on the same one. Some stop because of cost or side effects. Some switch. A Cleveland Clinic study presented at ObesityWeek, the big obesity medicine meeting that wrapped up Tuesday, followed 20,486 of those people for two years. According to Healio's report, the ones who stopped had kept the least weight off.

This article reports medical news and is not medical advice. SmashMeals is a food company, not a medical provider, and is not affiliated with the companies or researchers named here. Talk with your prescriber before you start, stop, switch or change any medicine.

What the researchers did

The team, led by Hamlet Gasoyan, PhD, of the Cleveland Clinic Center for Value-Based Care Research, used the health system's electronic records from 2021 to 2025. They included adults with type 2 diabetes or obesity who were on once-weekly injectable semaglutide (the medicine in Wegovy and Ozempic) or tirzepatide (the medicine in Zepbound and Mounjaro). The average patient was 56.7 years old, and 63% were women.

They used a method called target trial emulation, which sets up records data to look like a trial, and compared five paths: keep taking the starting medicine, switch between semaglutide and tirzepatide, switch to a different obesity drug, have bariatric surgery, or stop treatment.

What they found at two years

PathAverage weight change at 2 years
Stopped treatment-3.9%
Switched to another obesity drug-8.1%
Kept taking original medicine-10.9%
Switched between semaglutide and tirzepatide-16%
Bariatric surgery-26.6%

Figures are from the per-protocol analysis as reported by Healio. People who started on semaglutide and moved to tirzepatide lost about 3 kg (about 6.6 pounds) more than those who stayed on semaglutide. People who started on tirzepatide and stayed on it lost about 4.5 kg (about 10 pounds) more than those who moved to semaglutide. Blood sugar (A1C) and blood pressure followed a similar pattern.

"Our study highlights the importance of continued obesity management," Gasoyan said, according to Healio. He said the results "could support patient-clinician discussions about alternative therapy options."

What it cannot tell you

This was not a randomized trial. People were not assigned to stop, switch or have surgery; they and their doctors chose. Those groups can differ in health, insurance, money and motivation, and records do not capture all of that. The data come from one health system. And an average of 3.9% for the group that stopped does not tell any one person what will happen to them.

The study also did not look at food. It cannot say whether eating habits made a difference for any group. If you are thinking about stopping or switching, that is a conversation for your prescriber.

Where food fits

For many people, appetite comes back when a GLP-1 medicine stops or changes. That is when a steady routine matters most: regular meals, enough protein, portions that are already set. Our GLP-1 maintenance meals page covers that stretch. Our GLP-1 meal planning page and the illustrative 7-day GLP-1 meal plan show how people build a week, and the Wegovy meal plan covers eating while on semaglutide. None of it replaces advice from your care team.

“When you're on a GLP-1 medication, what you eat matters more, not less. You need high-protein, portion-controlled, nutrient-dense food — and you need to know it's safe. That's exactly what we do.” — Lew Kizer, Founder, SmashMeals

Pick up locally or order for shipping; checkout confirms timing. See this week's meals.

Commentary, not medical advice

The SmashMeals perspective

Whatever path a person and their doctor pick, the eating part does not stop. Some people stay on a medicine, some switch, some stop. All of them still need meals that are portioned and protein-forward. We cook those in our 100% gluten-free kitchen and post the nutrition so the numbers are easy to see.

Frequently asked questions

Do people regain weight after stopping a GLP-1?

In this study, people who stopped treatment were still down 3.9% of body weight on average two years after starting, compared with 10.9% for people who kept taking their medicine. That suggests many regained much of what they lost, but averages hide a wide range, and this study did not report individual paths.

Is switching from semaglutide to tirzepatide better?

In this study, people who started on semaglutide and switched to tirzepatide lost about 3 kg more at two years than those who stayed on semaglutide. The study was not randomized, so it cannot say switching caused the difference. Switching is a decision for you and your prescriber.

Why did the bariatric surgery group lose the most?

Surgery groups often show the largest weight loss, but people who choose surgery differ from people who do not in many ways. The groups were not randomly assigned, so they are not directly comparable.

Was this a clinical trial?

No. It was a target trial emulation, a method that uses health records to mimic a trial. It used data from one health system. The results are associations.

What should I eat if I am stopping my GLP-1?

This study did not test diet. Many people find that appetite comes back after stopping, so a plan for regular, portioned meals with enough protein can help with routine. Ask your care team or a registered dietitian what fits you.

Sources and credits

Follow the original sources for context and verification. A reference is not an endorsement of SmashMeals.

More SmashMeals news

Order Meals — View This Week's Menu